Robeauté Bets on Rice-Sized Microrobots for Brain Disease
Summary
French neurotechnology startup Robeauté is developing rice-sized microrobots to deliver drugs and other therapies to hard-to-reach areas of the brain. CEO Joana Cartocci says the company is targeting first-in-human studies in 2027 and a commercial launch in the early 2030s.
Robeauté is moving its technology from an engineering proposition toward a clinical development timeline, but
Unlock the full First Pass Analysis to get a better understanding of why this story matters
Why it matters
The company is pursuing a potentially new way to overcome one of neurology's central treatment barriers: delivering therapies precisely inside the brain.